GlassScriptPhysician profile
Ikedinobi U Eni
NPI 1629039938
$3,780.80
in general payments reported to CMS, 2019-2025
30 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $678 · 2021: $843 · 2022: $453 · 2023: $415 · 2024: $530 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $776.98 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $522.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $490.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $437.65 | 2019-2025 | |
| Abbott Laboratories | $206.64 | 2019-2024 | Freestyle Libre 3 |
| Abbvie INC. | $171.91 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.86 | 2020-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $166.23 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.73 | 2019-2022 | |
| Exact Sciences Corporation | $79.36 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $77.47 | 2020-2022 | |
| Amgen INC. | $54.46 | 2022-2024 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $50.97 | 2023-2024 | Gemtesa |
| Allergan, INC. | $44.89 | 2020 | |
| Dexcom, INC. | $43.82 | 2023 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $35.59 | 2019-2021 | |
| Glaxosmithkline, LLC. | $34.31 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $32.31 | 2022 | |
| Abiomed | $26.92 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.00 | 2024 | Voquezna |
| Astellas Pharma US INC | $22.56 | 2024 | Veozah |
| Horizon Therapeutics Plc | $19.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.05 | 2022 | |
| Amarin Pharma, INC. | $17.32 | 2019 | |
| Eisai INC. | $16.97 | 2021 | |
| Merck Sharp & Dohme LLC | $15.74 | 2019 | |
| Vivus LLC | $14.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikedinobi Eni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.